Clinical Evidence — Trials, Mechanism, Safety

Clinical reference

STEP Trial Results
STEP-1 through STEP-4 trials established semaglutide's weight-management efficacy. Pivotal STEP-1 (NEJM 2021, PMID 33567185): 14.9 SUSTAIN Trial Results
SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approva SELECT Trial Results
SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Weg FLOW Trial Results
FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years. Mechanism of Action
Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric em Contraindications & Boxed Warning
Semaglutide is contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Boxed warning: thyroid C-cell tumors (rodent studies, huma Side Effects
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serio Dosing & Pharmacology
Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly. Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg weekly. Rybelsus: 3 → 7 → 14 mg daily oral. Drug Interactions
Key interactions: oral medications (delayed gastric emptying), insulin and sulfonylureas (hypoglycemia risk), oral contraceptives

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing